Sun Pharma launches new anti-inflammatory drug Ilumya in the U.S. for treatment of adult patients with moderate to severe plaque psoriasis

recently, Indian drugmaker
Sun Pharma announced the launch of the anti-inflammatorynew drug(tildrakizumab-asmn, 100mg/mL) in the United States for the treatment of adults with moderate to severe plaque psoriasis for systemic or phototherapyIlumya's medication regimen is 100mg of subcutaneous injections in the 0th and 4th weeks, followed by 100mg of subcutaneous injections every 3 monthsthe activedrugof IlumyaIlumya (ingredient tildrakizumab, a humanized monoclonal antibody that selectively and highaffinity binds to THE p19 subunit of IL-23, inhibiting the results of its and IL-23 receptors, thereby inhibiting the release of pro-inflammatory cytokines and prosthesis factorsIlumya will provide patients with a simple treatment plan, after the completion of the first treatment of the 0th and 4th weeks, the follow-up maintenance treatment period every 3 months of subcutaneous injection, that is, only 4 times a year, will provide patients with greater convenience, achieve better disease control, improve treatment satisfactiontildrakizumab was originally developed by Mercado, and Sun Pharma took the exclusive global interest in Tildrakizumab in September 2014 for an $80 million advance paymentIn July 2016, Almirall paid Sun Pharma a $50 million advance payment for tildrakizumab's exclusive interest in EuropeIn the U.Smarket, tildrakizumab was approved in March 2018 under the brand name Ilumya, and in the European market, tildrakizumab was approved in September 2018 under the brand name Ilumetri